



Select Other Country | Contact Us



EYLEA® (afibercept solution for injection)

# Once every 2 months<sup>a</sup> dosage regimen for treatment of wet age-related macular degeneration (AMD)

Efficacy

Summary of Product Characteristics



Safety Information

**Administration**

Press Release



The recommended dose of EYLEA is 2 mg (equivalent to 50 microliters solution for injection).

EYLEA treatment is initiated with 1 injection per month (every 4 weeks) for 3 consecutive doses, followed by 1 injection every 2 months (8 weeks). There is no requirement for monitoring between injections.

## EYLEA administration schedule in the first year



Long term (after the first 12 months of treatment), it is recommended that patients continue to be treated with EYLEA every 2 months (8 weeks). However, after the first 12 months of treatment with EYLEA, the treatment interval could be extended up to every 3 months (12 weeks) based on visual and anatomic outcomes.

EYLEA may be dosed as frequently as once per month (4 weeks).

<sup>a</sup>Following 3 initial monthly treatments.

Please read the [Summary of Product Characteristics](#) for EYLEA.

<sup>\*</sup>Data on file. EYLEA Expanded Company Core Data Sheet (CCDS). Version 5. February 14, 2012. Bayer HealthCare, Regeneron.

Bayer Global

Imprint

EYLEA Portal

Bayer HealthCare

Conditions of Use

Summary of Product Characteristics

Bayer Pharma

Privacy Statement

References

© 2012 Bayer Pharma AG.  
This website contains information on EYLEA (afibercept) which is based on the Summary of Product Characteristics (SPC) as approved by the European Commission. It is intended to provide information to an international audience outside the USA and UK.  
Last updated on x-xx-xxxx.